Indeed, a recent (5/24/2020) search of ClinicalTrials.gov revealed at least 62 clinical trials examining the efficacy and safety of α-IL-6R mAbs and α-IL-6 mAbs for management of patients with COVID-19; 45 studies for tocilizumab (α-IL-6R mAbs), 14 for sarilumab (α-IL-6R mAbs) and 3 for siltuximab (α-IL-6 mAbs). Here, IL6R is linked to COVID-19.